Published in BMC Infect Dis on February 26, 2013
Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrob Agents Chemother (2014) 0.85
Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother (2014) 0.83
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. Curr Fungal Infect Rep (2015) 0.83
Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother (2015) 0.78
Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrob Agents Chemother (2016) 0.78
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother (2016) 0.78
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med (2013) 0.76
Voriconazole and the liver. World J Hepatol (2015) 0.75
PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics (2017) 0.75
Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatr Infect Dis J (2017) 0.75
Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients. J Res Pharm Pract (2017) 0.75
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform (2008) 71.12
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol (2003) 4.31
Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother (2006) 2.89
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2005) 2.07
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother (2012) 2.05
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.67
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer (2007) 1.65
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly (2006) 1.61
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother (2011) 1.41
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit (2011) 1.24
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother (2012) 1.11
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother (2006) 1.09
Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy (2011) 1.07
Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.03
Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother (2010) 1.00
Measurement of voriconazole in serum and plasma. Clin Biochem (2007) 1.00
Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J (2011) 0.98
Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother (2009) 0.92
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis (2011) 0.88
Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother (2011) 0.86
Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit (2012) 0.86
Dosing voriconazole in an obese patient. Clin Infect Dis (2011) 0.85
Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies. Med Mycol (2012) 0.83
Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother (2010) 0.80
Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit (2010) 0.80
[Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene]. Jpn J Antibiot (2010) 0.78
In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology. Mycoses (2009) 0.77
Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring? Ther Drug Monit (2009) 0.77
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry (2010) 2.34
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood (2013) 2.22
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood (2011) 1.80
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
The effect of gastric Acid on the absorption of posaconazole. Clin Infect Dis (2008) 1.69
Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health (2005) 1.65
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med (2012) 1.59
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis (2003) 1.58
Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant (2013) 1.58
HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood (2011) 1.28
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood (2011) 1.20
Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis (2011) 1.14
Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis (2014) 1.12
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav (2007) 1.11
Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant (2013) 1.09
HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 1.08
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One (2013) 1.07
Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis (2009) 1.07
An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2010) 1.06
Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays. Appl Environ Microbiol (2009) 1.06
Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis (2013) 1.05
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00
Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat (2009) 0.99
Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One (2012) 0.99
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98
Is lower 30-day mortality posthospital admission among blacks unique to the Veterans Affairs health care system? Med Care (2007) 0.98
Gender differences in the risk of HIV infection among persons reporting abstinence, monogamy, and multiple sexual partners in northern Tanzania. PLoS One (2008) 0.98
Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med (2015) 0.96
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant (2012) 0.93
Micafungin: a new echinocandin antifungal. Pharmacotherapy (2007) 0.93
Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant (2010) 0.93
Early pregnancy changes in bacterial vaginosis-associated bacteria and preterm delivery. Paediatr Perinat Epidemiol (2014) 0.88
Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med (2009) 0.87
Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One (2012) 0.87
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine (2013) 0.87
Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT. Biol Blood Marrow Transplant (2009) 0.87
Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. J Acquir Immune Defic Syndr (2016) 0.85
Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. J Infect Dis (2012) 0.85
Identifying risk factors for marijuana use among veterans affairs patients. J Addict Med (2010) 0.85
Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis (2013) 0.84
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav (2009) 0.83
Dapsone interferes with hemoglobin A1c monitoring of diabetes in an HIV-infected patient. AIDS (2013) 0.82
Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol (2012) 0.81
Associations between vaginal bacteria and levels of vaginal defensins in pregnant women. Am J Obstet Gynecol (2012) 0.80
Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05. Sex Transm Dis (2011) 0.80
Human herpesvirus 8 and sarcoidosis. Clin Infect Dis (2002) 0.80
Enhanced fungal DNA-extraction from formalin-fixed, paraffin-embedded tissue specimens by application of thermal energy. Med Mycol (2012) 0.80
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol (2012) 0.79
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS (2016) 0.79
Role of antibiotics for the prevention of cardiovascular disease. Ann Pharmacother (2002) 0.78
Relationship of selected bacterial vaginosis-associated bacteria to Nugent score bacterial vaginosis among urban women early in pregnancy. Sex Transm Dis (2013) 0.77
Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. Leuk Lymphoma (2014) 0.77
Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infect Dis (2012) 0.77
The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. Clin Infect Dis (2009) 0.76
49th ICAAC annual meeting: optimization of anti-infective use in the clinical setting. Expert Rev Anti Infect Ther (2009) 0.76
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. Br J Haematol (2014) 0.75
Semen Bacterial Concentrations and HIV-1 RNA Shedding among HIV-1-Seropositive Kenyan Men. J Acquir Immune Defic Syndr (2016) 0.75
Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial. Am J Addict (2008) 0.75
Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation (2014) 0.75
Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause (2017) 0.75
The forest for the trees: tuberculosis control efforts in west Kalimantan. Trop Doct (2010) 0.75
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. bioRxiv (2020) 0.75
Human Metapneumovirus and Other Respiratory Viral Infections during Pregnancy and Birth, Nepal. Emerg Infect Dis (2017) 0.75
Demystifying MRSA. Drug-resistant bacteria threatens HIV community. Posit Aware (2007) 0.75